Alzamend Neuro ALZN 深 沪
等待开盘 08-20 09:30:00 美东时间
1.52
0.000
0.00%
华盛通- 最 高1.60
- 今 开1.50
- 成交量 9.51万股
- 最 低 1.50
- 昨 收 1.52
- 总市值 728.31万
- 52周最高 2.68
- 市盈率 静 --
- 换手率 1.99%
- 52周最低 0.84
- 委 比 35.38%
- 总股本 479.15万
- 历史最高 45292.50
- 量 比 1.67
- 振 幅 6.58%
- 历史最低 0.84
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
今天 08:39
Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised the price target for Mercury Systems Inc (NASDAQ:MRCY) from $126 to $131. Piper Sandler a...
08-19 20:23
Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raises the price target from $25 to $26.
08-19 18:06
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop
ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001, Alzamend's ...
08-18 20:06
Alzamend Neuro Signs $25M Securities Purchase Agreement With Ault Lending; Alzamend Receives $7.5M In Gross Proceeds Form Initial Tranche
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announce...
08-04 20:12
Alzamend Neuro Announces Passing of Board Director
An update from Alzamend Neuro ( ($ALZN) ) is now available. Alzamend Neuro, Inc...
07-22 05:09
美股夜盘 | 707 Cayman Holdings涨154.16%，Globavend Holdings Ltd.涨22.92%
因立夫涨-43.13%；柏雅国际涨-17.28%；Core Al涨-6.95%
07-01 08:05
Alzamend Neuro Announces Pharmacodynamic Findings From Brain Magnetic Resonance Spectroscopy Analysis Conducted In Healthy Human Subjects In Trial Conducted At Massachusetts General Hospital
Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a
04-07 20:15
Alzamend Announces Topline Data From First Phase II "Lithium In Brain" Clinical Trial, Demonstrating AL001 Meets Bioequivalence Standards, And Showing Numerically Superior Lithium Delivery To Brain Compared To Standard Lithium Carbonate
Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain Penetration: AL001 showed numerically higher lithium
03-26 20:08
